News
La prueba de sangre para el alzhéimer de Roche y Eli Lilly recibe autorización de la FDA
Summary by The El Paso Editorial Desk CNN Newsource , as published by KVIA ABC-7
· August 25, 2026
· 1 min read
Photo: KVIA ABC-7 · view original
Story provenance No corrections
Summary created by The El Paso Editorial Desk — automated, rule-governed Byline on source page CNN Newsource, as published by KVIA ABC-7 Original story Read at the source Source published Aug 25, 2026 Indexed here Aug 25, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key points The test, Elecsys pTau217, is a blood biomarker analysis that can aid doctors in identifying patients who may or may not have Alzheimer's-related brain changes. It is intended for individuals 55 and older with cognitive decline.
The US Food and Drug Administration has authorized a blood test to help identify signs of Alzheimer's disease. The test, Elecsys pTau217, is a blood biomarker analysis that can aid doctors in identifying patients who may or may not have Alzheimer's-related brain changes. It is intended for individuals 55 and older with cognitive decline.
The test was previously approved in Europe in May. Over 4,500 laboratory analyzers are already installed in the US, which could help expand access to the test. Labcorp and Quest Diagnostics have announced plans, although details are not specified.
Further information on the test and its availability can be found through the source. The authorization marks a development in the detection of Alzheimer's disease, with the test potentially helping to identify signs of the condition.
More News Today’s briefing Local events
Why this story is here
KVIA ABC-7 reported and published this story. The El Paso selected it, summarised the key facts above, and links to the original. We did not report this story and we added no reporting of our own to it.
About this story
As published by KVIA ABC-7 . The El Paso selects stories from publishers’ feeds, summarises them, and links back to the publisher that reported them. We add no reporting of our own. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit KVIA ABC-7 . Have a tip or correction? Contact the editor .
Category: News Published: August 25, 2026 Source: KVIA ABC-7 Reading time: 1 min
Frequently asked about this story
What is this story about? The US Food and Drug Administration has authorized a blood test to help identify signs of Alzheimer's disease. The test, Elecsys pTau217, is a blood biomarker analysis that can aid doctors in…
When was this published? This article was first published on August 25, 2026 by KVIA ABC-7 and curated for The El Paso readers.
Who reported this story? This story was reported by CNN Newsource at KVIA ABC-7. To learn more about how The El Paso selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more News coverage from The El Paso, or browse our daily briefing and topic hubs .
← Back to all news
More News →
Today’s briefing
Subscribe to newsletter
